ArticleTranslational cancer research2025
Development and validation of a nomogram comprising GLUT1 and clinical characteristics for predicting overall survival in intrahepatic cholangiocarcinoma.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Targeting Glycolytic Metabolism in Cancer Therapy: Current Approaches and Future Perspectives.Cells · 2026Review
- Integrin αvβ3 is a Potential Therapeutic Target in Cholangiocarcinoma.International journal of medical sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Intrahepatic cholangiocarcinoma (iCCA) is a highly aggressive malignancy arising from the intrahepatic bile duct epithelium, with increasing global incidence and poor prognosis due to late diagnosis and limited therapeutic options. Current prognostic models such as tumor-node-metastasis (TNM) staging exhibit suboptimal accuracy and lack integration of molecular biomarkers. Our study aims to explore the prognostic significance of Methods: We analyzed Results: TCGA data showed significant upregulation of Conclusions: Our study establishes GLUT1 as an independent prognostic biomarker and provides a clinically applicable tool for individualized risk stratification. While our nomogram shows promise for guiding postoperative management, its single-center design warrants external validation in future multi-center studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.